Claims
- 1. A method for reversing malignant phenotype in tissue by administering an effective amount of an .beta..sub.1 integrin function-blocking antibody or a peptide inhibitor of integrin function to the .beta..sub.1 integrin receptors of tissue in need of such treatment.
- 2. The method of claim 1 wherein the concentration of the antibody is from about 50 .mu.gram/ml to about 1000 .mu.gram/ml IgG.sub.1 administered in a biologically compatible fluid.
- 3. The method of claim 2 wherein the concentration of the antibody is from about 100 .mu.gram/ml to about 500 .mu.gram/ml IgG.sub.1 administered in a biologically compatible fluid.
- 4. The method of claim 3 wherein the concentration of the antibody is about 100 .mu.gram/ml IgG.sub.1 administered in a biologically compatible fluid.
- 5. The method of claim 2 wherein the concentration of the antibody is about 1 mg/ml IgG.sub.1 administered in a biologically compatible fluid.
- 6. The method of claim 4 wherein the concentration of antibody is about 100 .mu.gram/ml IgG.sub.1 administered in a biologically compatible solution.
- 7. The method of claim 6 wherein the tissue is a tissue expressing .beta..sub.1 integrin receptors.
- 8. The method of claim 7 wherein the tissue is selected from the group consisting of breast carcinoma tissue, prostate carcinoma tissue, intestinal tissue, or epithelial tissue.
- 9. The method of claim 1, wherein the .beta..sub.1 integrin function-blocking antibody is selected from the group consisting of rat monoclonal AIIB2 (American Type Culture Collection Accession Number 1008371), an antigen binding fragment of monoclonal AIIB2, mouse monoclonal JB1a (also referred to as J10: CHIEMICON catalogue #1965) and an antigen binding fragment of monoclonal JB1a.
Parent Case Info
This application is a divisional of U.S. Ser. No. 08/726,230, filed on Oct. 4, 1996, now U.S. Pat. No. 5,846,536.
Government Interests
This invention was made with U.S. Government support under Contract No. DE-AC03-76SF00098 between the U.S. Department of Energy and the University of California for the operation of Lawrence Berkeley Laboratory. The U.S. Government may have certain rights in this invention.
Divisions (1)
|
Number |
Date |
Country |
Parent |
726230 |
Oct 1996 |
|